BRIEF-Sosei Group says $10 million milestone payment from Astrazeneca to Heptares

* Says Heptares Therapeutics, the wholly-owned subsidiary of

Sosei Group Corporation, reported that it has been notified by

its partner AstraZeneca that the first subject has been dosed

with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1

clinical study, triggering a US$10 million payment from

AstraZeneca

Read more